Next-Generation DMSO-Free & Serum-Free Cryopreservation For Cell And Gene Therapy

By Mark Kline, Ph.D.1, Arthi Shridhar, Ph.D.1,Steve Oh, Ph.D.2, Alan Lam, Ph.D.2, and Simon Cool, Ph.D.2, Renata Gilfanova, Ph.D.3,Philip Norris, Ph.D.3,Marcus Muench, Ph.D.3,Todd McDevitt, Ph.D.4,Xiaoxi Wei, Ph.D.1 X-Therma Inc., Berkeley1; Agency for Science, Technology and Research, Singapore2; Vitalant Research Institute, San Francisco3. Gladstone Institutes, San Francisco4

Existing standards in cryopreservation use 5-10% dimethyl sulfoxide (DMSO) and often serum. These products have not been significantly improved for over 50 years. DMSO exhibits acute toxicity in patients and causes adverse cell mutation at low levels (0.1%) including irreversible cell chromosome damage and alterations in the epigenetic landscape. Serum remains a black box, inherently introducing batch-to-batch variability, diminished clinical reproducibility, and compromised precision in therapeutic delivery. However, performance in available DMSO & serum-free solutions is often compromised, warranting urgent advancement.

Learn about XT-Thrive®, a completely defined, non-toxic cryopreservation solution for cell & gene therapy and cell banking applications at ultra-low temperatures (-70°Cto-196°C). Formulated without any DMSO, serum, or recombinant proteins, every component is fully identified and quantified for superior compatibility with cGMP manufacturing processes.